

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.  
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540

BALTIMORE  
INNER HARBOR CENTER  
400 EAST PRATT STREET, SUITE 800  
BALTIMORE, MARYLAND 21202  
(410) 659-7570

BOF  
Sequence  
1812

DONALD J. FEATHERSTONE  
STEVEN R. LUDWIG  
LAWRENCE B. BUGAISKY  
KAREN R. MARKOWICZ  
DREW GRANSTON  
MICHAEL V. MESSINGER  
DAVID C. ISAACSON  
MEGAN D. DORTENZO  
THOMAS M. DUNHAM

REGISTERED  
PATENT AGENTS

WRITER'S DIRECT NUMBER:



ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. EDMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOLOV  
WILLIAM C. ALLISON  
MICHAEL O. LEE  
EVELYN H. MCCONATHY  
ERIC K. STEFFE  
ANDREA G. REISTER  
DANIEL N. YANNUZZI  
CONO A. CARRANO  
G. KEVIN TOWNSEND\*  
JOHN M. COVERT\*  
ANNE BROWN  
MICHELE A. VAN PATTEN\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
PAUL A. BERNKOPF\*  
ROBERT C. MILLONIG

JAMES L. LEWIS\*  
OF COUNSEL

\*BAR OTHER THAN D.C.

December 8, 1995

18C  
12-7-95  
RECEIVED

DEC 14 1995

GROUP 1800

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 08/249,671; Filed: May 26, 1994  
For: **Process for Preparing and Purifying Alpha-Interferon**  
Inventors: Hauptmann *et al.*  
Our Ref: 0652.1350000/RWE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Form PTO-1083 (in duplicate);
2. Amendment and Response Under 37 C.F.R. §§ 1.111 and 1.115; Amendment to Sequence Listing Under 37 C.F.R. § 1.825;
3. Paper and computer readable copy of Sequence Listing;
4. Copy of standard genetics text *Genes and Genomes* (Singer *et al.*, University Science Books, pp. 625-626, 1991);
5. Copy of J. E.F. Reynolds, ed., *Martindale*, The Pharmaceutical Press, London, p. 1270 (28th ed., 1982);

Assistant Commissioner for Patents  
December 8, 1995  
Page 2

6. Copy of Pestka, S., *et al.*, *Ann. Rev. Biochem.* 56: 730, 1987;
7. Certified copies of 35 U.S.C. § 119 priority applications, German application P 43 17 459.0, and German application P 43 29 756.0;
8. Copy of the Information Disclosure Statement, Form PTO-1449 (7 pages), and cited non-patent documents (AR1, AS1, AT1, AR2, AS2, AT2, AR3, AS3, AT3, AR4, AS4, AT4, AR5, AS5, AT5, AR6, AS6, AT6, AR7, AS7, and AT7) originally filed on November 15, 1994 (Paper No. 7); and
9. A return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

RWE/LLK/ttp  
p:\users\tpittman\0652\652135.CVR



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HAUPTMANN et al.

Appl. No.: 08/249,671

Filed: May 26, 1994

For: **Process for Preparing and Purifying  
Alpha-Interferon**

RECEIVED

DEC 14 1995

GROUP 1800

Art Unit: 1812

Examiner: Fitzgerald, D.

Atty Docket: 0652.1350000/RWE

12/8  
DQJ  
2/29/96

**Amendment and Response Under 37 C.F.R. §§ 1.111 & 1.115;  
Amendment to Sequence Listing Under 37 C.F.R. § 1.825**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Responsive to the Office Action dated September 8, 1995 (Paper No. 9), Applicants respectfully request reconsideration and reexamination of the above-captioned patent application in view of the following Amendment and Remarks.

***In the Specification:***

At p. 4, l. 20, before "exchange" please insert --cation--.

At p. 4, l. 21, before "exchange" please insert --anion--.

At p. 4, l. 27, please delete "9-10" and insert therefor --8-9--.

At p. 5, l. 5, please delete "11-12" and insert therefor --10-11--.

At p. 5, l. 12, please delete "phenylsepharose" and insert therefor --phenyl Sepharose™--.

At p. 5, l. 18, please delete "sepharose" and insert therefor --Sepharose Fast Flow™--.

B